The Cooper Companies, Inc. (COO) Average EV/EBITDA Ratio
The current ev/ebitda ratio for The Cooper Companies, Inc. (COO) is 17.97x as of Sunday, June 14, 2026, shown against its trailing averages.
Average EV/EBITDA Ratio Chart
COO EV/EBITDA Ratio Averages
EV/EBITDA RATIO CURRENT
17.97x
EV/EBITDA RATIO TTM
15.95x
EV/EBITDA RATIO 3Y
20.14x
EV/EBITDA RATIO 5Y
21.92x
EV/EBITDA RATIO 10Y
22.78x
EV/EBITDA RATIO 15Y
20.62x
EV/EBITDA RATIO 20Y
18.50x
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White